OPKO Health (NASDAQ: OPK - Get Free Report) is projected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $139.7570 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE's performance and strategic partnerships.
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time.
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Institutional and Insider Ownership 64.6% of OPKO Health
This is the third program that s uccessfully combine s Entera's oral peptide N- Tab ® platform with OPKO 's advanced protein chemistry capabilities
I believe OPKO Health will end 2026 on a high note. In partnership with Merck, Regeneron, and BARDA, it is developing ModeX's product candidates aimed at treating COVID-19, influenza, solid tumors, and blood cancers, as well as vaccines against EBV. Additionally, OPKO's balance sheet continues to strengthen, with total debt reaching $395.4 million at the end of Q3, down 22.8% year-over-year.
OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) shares passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.32 and traded as low as $1.2715. OPKO Health shares last traded at $1.28, with a volume of 1,691,533 shares. Analyst Upgrades and Downgrades Several
Positron (OTCMKTS:POSC - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Insider and Institutional Ownership 64.6% of OPKO Health
OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time.
